Drug Profile
Research programme: cardiovascular disorder therapeutics - Elyson Pharma
Alternative Names: ELI 1501Latest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator Elyson Pharm
- Class Anti-ischaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for preclinical development in Cardiovascular-disorders in South Korea
- 17 Feb 2017 Preclinical trials in Cardiovascular disorders in South Korea before February 2017 (Elyson Pharm pipeline, February 2017)
- 17 Feb 2017 Elyson Pharm announces intention to submit IND for ELI 1501 (Elyson Pharm pipeline, February 2017)